Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Research News
back to News Search
News Brief—Dead End for Lilly mGluR Schizophrenia Drug

29 August 2012. Eli Lilly and Company announced in a press release today that they will stop Phase 3 clinical trials of a schizophrenia drug targeting the metabotropic glutamate receptor. This was not unexpected, as just last month Lilly had revealed further disappointing trial results of the mGluR2/3 agonist pomaglumetad methionil (also called LY2140023). At the time, researchers interviewed by SRF had mixed opinions about the way forward (see SRF news story), and a Lilly spokesperson had told SRF that they were still pressing forward with the development of LY2140023, including analyzing data on mGluR2/3 agonists as adjunctive therapy to approved schizophrenia drugs. In the latest press release, they write that this Phase 2 study also failed to meet its primary endpoint.—Hakon Heimer.

 
Submit a Comment on this News Article
Make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Affiliation  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Password  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
 
Enter the code as it is shown below:
This code helps prevent automated registrations.

Please note: A member needs to be both registered and logged in to submit a comment.

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright